An Evidence-Based Approach to the Diagnosis and Management of Seborrheic Dermatitis: A Systematic Review
Keywords:
Seborrheic Dermatitis, Dandruff, Malassezia, Ketoconazole, Roflumilast, Systematic Review, Treatment AlgorithmAbstract
Introduction: Seborrheic dermatitis (SD) is a prevalent, chronic inflammatory skin disorder with a significant impact on patient quality of life. Its pathogenesis is multifactorial, involving an interplay between Malassezia yeast, host immune response, and skin barrier integrity. While numerous treatments exist, an updated synthesis is needed to integrate novel therapies into the clinical management algorithm. This systematic review aims to critically appraise and synthesize high-level evidence from randomized controlled trials (RCTs) on the efficacy and safety of interventions for SD in adolescents and adults.
Methods: A systematic search of PubMed, Google Scholar, Semanthic Scholar, Springer, Wiley Online Library was conducted to identify RCTs evaluating pharmacological or procedural interventions for SD. Studies were selected based on pre-defined inclusion criteria. Data on study design, patient characteristics, interventions, and outcomes were extracted. The methodological quality of included studies was assessed using the Cochrane Risk of Bias tool.
Results: Seventeen RCTs met the inclusion criteria. The evidence confirms the efficacy of first-line topical therapies, including antifungals (ketoconazole, ciclopirox) and anti-inflammatory agents (corticosteroids, calcineurin inhibitors). Ketoconazole 2% formulations are consistently superior to vehicle (e.g., treatment success of 25.3% vs. 13.9%, P=0.0014) and prophylactic use reduces relapse. Ciclopirox demonstrates non-inferiority and, in some cases, superiority to ketoconazole in maintenance phases. The novel phosphodiesterase-4 (PDE-4) inhibitor, roflumilast 0.3% foam, demonstrated significantly higher rates of Investigator Global Assessment (IGA) Success compared to vehicle at week 8 (79.5% vs. 58.0%; P<0.001) with a favorable safety profile. For recalcitrant disease, oral itraconazole was significantly more effective than placebo in improving severity scores (P=0.023) and reducing recurrence (P=0.003). Other therapies, including lithium salts and tea tree oil, also showed significant efficacy in controlled trials.
Discussion: The therapeutic landscape for SD is evolving from a primary focus on microbial control to a dual approach that also targets host inflammation. The high efficacy and safety of roflumilast foam, the first new mechanism of action approved for SD in over two decades, facilitates a paradigm shift from reactive flare management to proactive, long-term maintenance of clearance without the risks of chronic corticosteroid use.
Conclusion: The management of SD should be stratified based on disease severity and location. Topical antifungals and the novel PDE-4 inhibitor roflumilast represent effective and safe first-line options. Short-term topical corticosteroids are useful for managing acute flares, while calcineurin inhibitors serve as steroid-sparing alternatives. Systemic antifungals are reserved for severe, refractory cases. This review provides an evidence-based framework to guide clinicians in optimizing therapeutic strategies for this chronic condition.
References
Clark, G.W., Pope, S.M. and Jaboori, K.A. (2015). 'Diagnosis and treatment of seborrheic dermatitis'. American Family Physician, 91(3), pp. 185-190. Available at: https://pubmed.ncbi.nlm.nih.gov/25822272/ (Accessed: 18 September 2025).
Tucker, D. and Masood, S. (2025). 'Seborrheic Dermatitis: Practice Essentials, Background, Pathophysiology'. Medscape. Available at: https://emedicine.medscape.com/article/1108312-overview (Accessed: 18 September 2025).
Borda, L.J. and Wikramanayake, T.C. (2015). 'Seborrheic Dermatitis and Dandruff: A Comprehensive Review'. Journal of Clinical and Investigative Dermatology, 3(2). Available at: https://ijdvl.com/etiopathogenesis-of-seborrheic-dermatitis/ (Accessed: 18 September 2025).
Merck Manual Professional Edition (2025). 'Seborrheic Dermatitis - Dermatologic Disorders'. Available at: https://www.merckmanuals.com/professional/dermatologic-disorders/dermatitis/seborrheic-dermatitis (Accessed: 18 September 2025).
Mayo Clinic (2025). 'Seborrheic dermatitis - Symptoms and causes'. Available at: https://www.mayoclinic.org/diseases-conditions/seborrheic-dermatitis/symptoms-causes/syc-20352710 (Accessed: 18 September 2025).
Borda, L.J. and Wikramanayake, T.C. (2015). 'Seborrheic Dermatitis and Dandruff: A Comprehensive Review'. Journal of Clinical and Investigative Dermatology, 3(2). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4852869/ (Accessed: 18 September 2025).
National Eczema Association (2025). 'Seborrheic Dermatitis: Causes, Symptoms, Treatment'. Available at: https://nationaleczema.org/types-of-eczema/seborrheic-dermatitis/ (Accessed: 18 September 2025).
Cleveland Clinic (2025). 'Seborrheic Dermatitis: Symptoms, Causes & Treatment'. Available at: https://my.clevelandclinic.org/health/diseases/14403-seborrheic-dermatitis (Accessed: 18 September 2025).
Ludmann, P. (2025). 'Seborrheic Dermatitis'. In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK551707/ (Accessed: 18 September 2025).
Dall'Oglio, F., Nasca, M.R. and Schwartz, R.A. (2025). 'Seborrheic Dermatitis Update: A Review of the Etiology and Treatment of Seborrheic Dermatitis'. Practical Dermatology. Available at: https://practicaldermatology.com/topics/other-dermatitis/seborrheic-dermatitis-update-a-review-of-the-etiology-and-treatment-of-seborrheic-dermatitis/24003/ (Accessed: 18 September 2025).
Wang, T.S. et al. (2024). 'The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis'. Journal of the American Academy of Dermatology. Available at: https://pubmed.ncbi.nlm.nih.gov/38958996/ (Accessed: 18 September 2025).
MSD Manual Professional Edition (2025). 'Seborrheic Dermatitis - Dermatologic Disorders'. Available at: https://www.msdmanuals.com/professional/dermatologic-disorders/dermatitis/seborrheic-dermatitis (Accessed: 18 September 2025).
Del Rosso, J.Q. (2013). 'Optimizing Treatment Approaches in Seborrheic Dermatitis'. The Journal of Clinical and Aesthetic Dermatology, 6(2), pp. 44–49. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3579488/ (Accessed: 18 September 2025).
Sparavigna, A., Tenconi, B. and Di Pietro, A. (2024). 'Seborrheic Dermatitis: From Microbiome and Skin Barrier Involvement to Emerging Approaches in Dermocosmetic Treatment'. Cosmetics, 11(6), p. 208. Available at: https://www.mdpi.com/2079-9284/11/6/208 (Accessed: 18 September 2025).
Theelen, B., Cafarchia, C. and Gaitanis, G. (2025). 'Seborrheic Dermatitis: Exploring the Complex Interplay with Malassezia'. International Journal of Molecular Sciences, 26(6), p. 2650. Available at: https://www.mdpi.com/1422-0067/26/6/2650 (Accessed: 18 September 2025).
Sanders, M.G.H. and Pardo, L.M. (2022). 'Seborrheic Dermatitis in Older Adults: Pathogenesis and Treatment Options'. Drugs & Aging, 39(4), pp. 251-261. Available at: https://pubmed.ncbi.nlm.nih.gov/35394260/ (Accessed: 18 September 2025).
Dessinioti, C. and Katsambas, A. (2013). 'Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies'. Clinics in Dermatology, 31(4), pp. 343-351. Available at: https://pubmed.ncbi.nlm.nih.gov/23806151/ (Accessed: 18 September 2025).
Turner, G.A., Hoptroff, M. and Harding, C.R. (2013). 'A Comprehensive Pathophysiology of Dandruff and Seborrheic Dermatitis – Towards a More Precise Definition of Scalp Health'. Acta Dermato-Venereologica, 93(2), pp. 131-137. Available at: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-1382 (Accessed: 18 September 2025).
Firooz, A. et al. (2013). 'Topical Pimecrolimus 1% Cream in the Treatment of Seborrheic Dermatitis: A Double-Blind Randomized Study'. Indian Journal of Dermatology, Venereology and Leprology, 79(2), p. 262. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3579486/ (Accessed: 18 September 2025).
Mayo Clinic (2025). 'Seborrheic dermatitis - Diagnosis and treatment'. Available at: https://www.mayoclinic.org/diseases-conditions/seborrheic-dermatitis/diagnosis-treatment/drc-20352714 (Accessed: 18 September 2025).
Arcutis Biotherapeutics, Inc. (2024). 'FDA Approves Arcutis' ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older'. Press Release. Available at: https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-topical-foam-0-3-for-the-treatment-of-seborrheic-dermatitis-in-individuals-aged-9-years-and-older/ (Accessed: 18 September 2025).
Dermatology Times (2025). 'Patrick Burnett, MD, PhD, Highlights Arcutis' New Seborrheic Dermatitis Initiative With Odell Beckham Jr.'. Available at: https://www.dermatologytimes.com/view/patrick-burnett-md-phd-highlights-arcutis-new-seborrheic-dermatitis-initiative-with-odell-beckham-jr- (Accessed: 18 September 2025).
Clark, G.W., Pope, S.M. and Jaboori, K.A. (2015). 'Diagnosis and Treatment of Seborrheic Dermatitis'. American Family Physician, 91(3), pp. 185-190. Available at: https://www.aafp.org/pubs/afp/issues/2015/0201/p185.html (Accessed: 18 September 2025).
Scaparro, E. et al. (2002). 'A randomised, single-blind, single-centre clinical trial to evaluate the comparative efficacy and safety of ketoconazole 2% emulsion and ketoconazole 2% shampoo in the treatment of moderate to severe seborrhoeic dermatitis of the scalp'. Journal of the European Academy of Dermatology and Venereology, 16(2), pp. 171-173. Available at: https://pubmed.ncbi.nlm.nih.gov/12060502/ (Accessed: 18 September 2025).
Paller, A.S. et al. (2024). 'Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis (INTEGUMENT‐PED): A Phase 3 Randomized Controlled Trial'. Pediatric Dermatology. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11950803/ (Accessed: 18 September 2025).
Lebwohl, M.G. et al. (2024). 'Roflumilast and the Changing Landscape of Seborrheic Dermatitis Treatment'. Journal of Drugs in Dermatology, 23(7). Available at: https://pubmed.ncbi.nlm.nih.gov/40635650/ (Accessed: 18 September 2025).
Koca, R. et al. (2015). 'Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial'. American Journal of Clinical Dermatology, 16(5), pp. 431-437. Available at: https://pubmed.ncbi.nlm.nih.gov/26016699/ (Accessed: 18 September 2025).
Gupta, A.K. and Bluhm, R. (2005). 'Seborrhoeic dermatitis'. Journal of the European Academy of Dermatology and Venereology, 19(1), pp. 13-26. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4445675/ (Accessed: 18 September 2025).
Skin Therapy Letter (2025). 'Roflumilast for the Treatment of Seborrheic Dermatitis: A Review'. Available at: https://www.skintherapyletter.com/dermatology/roflumilast-seborrheic-dermatitis/ (Accessed: 18 September 2025).
Lebwohl, M.G. et al. (2024). 'Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: Two phase 3, randomized, double-blind, vehicle-controlled trials (STRATUM)'. Journal of the American Academy of Dermatology, 90(5), pp. 934-941. Available at: https://pubmed.ncbi.nlm.nih.gov/38253129/ (Accessed: 18 September 2025).
Satchell, A.C. et al. (2002). 'Efficacy of Melaleuca alternifolia Essential Oil in the Treatment of Facial Seborrheic Dermatitis: A Double-blind Randomized Placebo-Controlled Clinical Trial'. Archives of Dermatology, 138(10), pp. 1349-1352. Available at: https://www.researchgate.net/publication/287371621_Efficacy_of_Melaleuca_alternifolia_Essential_Oil_in_the_Treatment_of_Facial_Seborrheic_Dermatitis_A_Double-blind_Randomized_Placebo-Controlled_Clinical_Trial (Accessed: 18 September 2025).
Koca, R. et al. (2016). 'Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial'. Journal of Dermatological Treatment, 27(4), pp. 315-318. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5006547/ (Accessed: 18 September 2025).
Pierard, G.E. et al. (2006). 'Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial'. Journal of Drugs in Dermatology, 5(7), pp. 646-650. Available at: https://pubmed.ncbi.nlm.nih.gov/16865870/ (Accessed: 18 September 2025).
Peter, R.U. and Richarz-Barthauer, U. (1995). 'Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial'. British Journal of Dermatology, 132(3), pp. 441-445. Available at: https://pubmed.ncbi.nlm.nih.gov/7718463/ (Accessed: 18 September 2025).
Danby, F.W. et al. (1993). 'A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff'. Journal of the American Academy of Dermatology, 29(6), pp. 1008-1012. Available at: https://pubmed.ncbi.nlm.nih.gov/8245236/ (Accessed: 18 September 2025).
Chosidow, O. et al. (2008). 'An open, randomized, prospective, comparative study of topical ketoconazole 2% emulsion and ketoconazole 2% shampoo in the treatment of seborrhoeic dermatitis of the scalp'. Journal of the European Academy of Dermatology and Venereology, 22(9), pp. 1113-1118. Available at: https://pubmed.ncbi.nlm.nih.gov/18677657/ (Accessed: 18 September 2025).
Ratnavel, R.C. and Squire, R.A. (2002). 'Randomized, open-labeled, non-inferiority study between ketoconazole 2% foam and ketoconazole 2% shampoo in the treatment of mild to moderate seborrhoeic dermatitis'. Journal of Dermatological Treatment, 13(2), pp. 51-59. Available at: https://pubmed.ncbi.nlm.nih.gov/12673081/ (Accessed: 18 September 2025).
Vena, G.A. et al. (2005). 'Treatment and prophylaxis of seborrheic dermatitis of the scalp with ciclopiroxolamine 1.5% shampoo'. Skinmed, 4(1), pp. 43-48. Available at: https://pubmed.ncbi.nlm.nih.gov/15655141/ (Accessed: 18 September 2025).
Rigopoulos, D. et al. (2003). 'An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis'. Journal of the European Academy of Dermatology and Venereology, 17(2), pp. 225-226. Available at: https://pubmed.ncbi.nlm.nih.gov/12833030/ (Accessed: 18 September 2025).
Dreno, B. et al. (2003). 'Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study'. British Journal of Dermatology, 148(6), pp. 1240-1244. Available at: https://pubmed.ncbi.nlm.nih.gov/12828753/ (Accessed: 18 September 2025).
Efalith Multicenter Trial Group (1992). 'A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis'. Journal of the American Academy of Dermatology, 26(3 Pt 2), pp. 452-457. Available at: https://pubmed.ncbi.nlm.nih.gov/1532964/ (Accessed: 18 September 2025).
Lebwohl, M. et al. (2002). 'A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis'. Cutis, 69(6), pp. 457-462. Available at: https://pubmed.ncbi.nlm.nih.gov/12077544/ (Accessed: 18 September 2025).
Kaur, I. et al. (2024). 'A New Purpose to Old Arsenal: Exploring the Safety and Efficacy of a New Regimen Comprising a Combination of Chlorhexidine Gluconate and Cetrimide for Seborrheic Dermatitis Treatment in a Randomized Placebo-Controlled Clinical Trial'. Indian Journal of Dermatology, 69(2), pp. 199-199. Available at: https://pubmed.ncbi.nlm.nih.gov/39463503/ (Accessed: 18 September 2025).
Cicek, D. et al. (2006). 'Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment'. Journal of the European Academy of Dermatology and Venereology, 20(10), pp. 1305-1309. Available at: https://pubmed.ncbi.nlm.nih.gov/17101479/ (Accessed: 18 September 2025).
Kastarinen, H. et al. (2019). 'Topical anti‐inflammatory agents for seborrhoeic dermatitis of the face or scalp'. Cochrane Database of Systematic Reviews, (5). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6483543/ (Accessed: 18 September 2025).
Koca, R. et al. (2011). 'ORAL ITRACONAZOLE FOR THE TREATMENT OF SEVERE SEBORRHOEIC DERMATITIS'. Journal of the Pakistan Association of Dermatologists, 21(1), pp. 30-34. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3221212/ (Accessed: 18 September 2025).
Koca, R. et al. (2008). 'Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study'. American Journal of Clinical Dermatology, 9(1), pp. 51-54. Available at: https://pubmed.ncbi.nlm.nih.gov/18669136/ (Accessed: 18 September 2025).
Dall'Oglio, F., Nasca, M.R. and Micali, G. (2022). 'An Overview of the Diagnosis and Management of Seborrheic Dermatitis'. Journal of Clinical Medicine, 11(15), p. 4503. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9365318/ (Accessed: 18 September 2025).
Naldi, L. and Rebora, A. (2000). 'Treatment of Seborrheic Dermatitis'. American Family Physician, 61(9), pp. 2703-2710. Available at: https://www.aafp.org/pubs/afp/issues/2000/0501/p2703.html/1000 (Accessed: 18 September 2025).
Silverberg, J.I. et al. (2024). 'Child and Adult Seborrheic Dermatitis: A Narrative Review of the Current Treatment Landscape'. American Journal of Clinical Dermatology. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11909311/ (Accessed: 18 September 2025).
U.S. Department of Veterans Affairs (2025). 'Seborrheic Dermatitis - Whole Health Library'. Available at: https://www.va.gov/WHOLEHEALTHLIBRARY/tools/seborrheic-dermatitis.asp (Accessed: 18 September 2025).
Bawaneh, A. et al. (2024). 'Nutrition, Obesity, and Seborrheic Dermatitis: Systematic Review'. JMIR Dermatology, 7, p. e50143. Available at: https://derma.jmir.org/2024/1/e50143 (Accessed: 18 September 2025).
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Lisa Anggraini (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
